What "human-in-the-loop" actually means when you deploy AI in a clinical setting

"Human-in-the-loop" is the phrase that lets a healthcare AI vendor close a sale. It signals safety, oversight, accountability, and clinician control. It is also one of the most loosely used terms in clinical AI, and the looseness is starting to matter.

In Australia, the TGA's 2026 review of safe and responsible AI in healthcare found that 88% of respondents said there should always be a human in the loop when AI is used to make decisions or deliver healthcare services. The same review noted that many respondents stressed the human needs to be "meaningfully" in the loop to be effective. AHPRA's professional guidance is similarly explicit: health practitioners remain responsible for delivering safe and quality care, and must apply human judgment to any output of AI.

This is broad consensus that something called "human-in-the-loop" is necessary. It is not consensus about what that something actually is.

This post is for clinical leaders signing off on AI deployments and the technical teams implementing what gets signed off. It distinguishes between three different things people mean when they say "human-in-the-loop," explains where each one is appropriate, and outlines what regulators and accreditors will increasingly expect to see.

Three different loops, three different jobs

When people say "human-in-the-loop" in clinical AI, they generally mean one of three things. They are not interchangeable, and conflating them is how AI governance promises fail under scrutiny.

Loop 1: Review-before-action

The clinician reviews and approves every AI output before it has any effect.

This is the strictest form of human-in-the-loop. The AI produces a draft, a recommendation, or a suggested action, and nothing happens until a qualified human signs off. The AI is functionally a productivity tool; the clinical authority remains entirely with the human.

This is the right loop for any AI workflow where the output directly informs clinical care: drafted clinical notes, suggested diagnoses, treatment recommendations, prior authorisation decisions affecting patient access to care.

The cost of this loop is throughput. Every AI output requires clinician time. The benefit is that the failure mode is bounded: if the AI is wrong, the clinician catches it before the patient is affected.

Loop 2: Sample-based audit

The clinician (or a clinical quality function) reviews a statistical sample of AI outputs to monitor system performance, rather than every individual output.

This is the right loop for high-volume, low-stakes-per-instance applications where review-before-action is operationally impossible. Examples include AI-driven coding suggestions, claims processing, or low-risk administrative workflows where errors are recoverable.

Sample-based audit is also the right pattern for ongoing quality assurance of systems that have a review-before-action loop in front of them. Even if every output is reviewed by a clinician, periodic audits of the AI's draft quality, citation accuracy, and bias patterns are necessary to catch systematic drift over time.

The cost of this loop is that some errors will reach production before being caught. The benefit is that the system can operate at scale, and a properly designed audit framework gives statistically valid confidence in overall quality.

Loop 3: Feedback loop tuning

Clinician corrections, overrides, and feedback are captured and used to improve the AI system over time.

This loop is not really about catching errors in the current workflow. It is about ensuring the AI system gets better at its job, that clinical edge cases are identified and addressed, and that the system stays aligned with evolving clinical practice.

A well-designed feedback loop captures not just whether a clinician accepted the AI output, but what they changed. The corrections themselves are valuable training signal: which medications get added, which conditions get re-coded, which recommendations get rejected.

This loop is necessary in any clinical AI deployment that will run for more than a few months. Without it, the AI cannot adapt to changes in clinical practice, new evidence, or population-specific patterns. With it, the system improves over time and the organisation learns where its AI investments are actually paying off.

Why conflating the loops is dangerous

The failure mode looks like this. A vendor says their product has "human-in-the-loop oversight," meaning they have a feedback mechanism (loop 3). The buyer hears it as review-before-action (loop 1). The product is deployed. AI outputs go directly into patient-facing workflows without per-instance review, because the buyer trusted the "oversight" framing. Six months later, a clinical incident reveals that nobody was actually reviewing the AI's outputs before they affected care.

This scenario is not theoretical. Variations of it have played out in health systems globally, and the regulatory response is sharpening accordingly. The TGA's January 2026 position is that AI-based software as a medical device requires explicit conformity assessment, not a general claim of "AI oversight." AHPRA's guidance places responsibility for AI outputs squarely on the clinician using them. Te Whatu Ora's AI governance framework in New Zealand similarly emphasises transparency and clinician accountability.

The implication for any healthcare provider deploying AI is that "human-in-the-loop" cannot be a single phrase in a procurement document. It has to be specified: which loop, for which use case, with what review burden, captured how, and audited by whom.

What good documentation of the loop looks like

Regulators, accreditors, and governance committees are increasingly looking for specific artefacts that prove human-in-the-loop design is operating in practice. The most useful ones are these.

A documented decision matrix for each AI use case. Which loop applies. Why this loop is appropriate for this use case. What clinical risk this loop is mitigating.

Override rates and patterns. How often clinicians override AI recommendations. Whether overrides cluster by clinician, by patient population, by clinical area, or by AI confidence level. Whether the override rate is trending up, down, or stable.

Audit logs that capture the full interaction. Not just the AI output, but the prompt or context that produced it, the clinician's response, and the timing. This is essential for incident investigation and increasingly expected for regulatory review.

Drift monitoring. Whether the AI's performance is degrading over time as clinical practice, data patterns, or patient populations evolve. This requires baseline performance metrics and a defined evaluation cadence.

Bias and equity monitoring. Whether the AI's accuracy or recommendations vary systematically by patient demographics, particularly for groups identified as priority populations under New Zealand's Te Tiriti obligations or Australia's Closing the Gap framework.

These artefacts are not optional extras. They are increasingly the difference between an AI deployment that survives a regulatory review and one that does not.

The "meaningful" part of "meaningfully in the loop"

The TGA review's emphasis on the human being meaningfully in the loop is worth dwelling on, because it points to a failure mode that is becoming more common.

It is possible to have a clinician technically reviewing every AI output while not meaningfully reviewing any of them. If a clinician is shown 100 AI-drafted notes per shift and the workflow encourages rapid approval, the review becomes a rubber stamp. The loop exists; the meaningful oversight does not.

The technical design choices that determine whether oversight is meaningful are subtle but important. Defaults matter (is the default action "approve" or "review"?). Friction matters (how easy is it to override?). Display matters (is the AI's reasoning visible, or just its conclusion?). Timing matters (does the clinician see the AI output before or after their own initial assessment?).

These are not edge cases. They are core design decisions, and they determine whether the human-in-the-loop is real or theatre.

A practical specification

For any healthcare AI deployment, the human-in-the-loop design should be specified with this level of detail:

Use case: What is the AI doing?
Loop type: Which of the three loops applies, and why?
Review trigger: What event prompts the human to act? Every output? Samples? AI confidence below a threshold?
Reviewer qualifications: Who is qualified to perform this review?
Time budget: How much time per review is realistic, and is that time available in the clinician's workflow?
Override mechanism: How does the clinician disagree with the AI? Is the override one click, or does it require justification?
Capture mechanism: How are the AI output, the clinician's response, and the rationale captured for audit?
Escalation path: What happens if the clinician is uncertain? Is there a second-line review?
Audit cadence: How often is the loop itself reviewed for effectiveness?

This level of specification is more work than "we have human-in-the-loop oversight." It is also what distinguishes deployments that work from deployments that fail under scrutiny.

What this means for buyers and builders

If you are buying healthcare AI, ask vendors which loop their system supports, not whether they have human-in-the-loop. Demand specifics. If the answer is vague, the design is probably also vague.

If you are building healthcare AI, design the loop before you design the model integration. The loop determines the workflow, the workflow determines the user interface, and the user interface determines whether clinicians actually use the system. Working backwards from the loop is more efficient than retrofitting it later.

If you are governing healthcare AI in a provider organisation, do not accept "human-in-the-loop" as an answer. Accept the documented decision matrix, the override data, the audit logs, the drift monitoring, and the bias review. The phrase is a starting point. The artefacts are the substance.

Three loops, three jobs. Get the right one for the right use case, specify it properly, and human-in-the-loop becomes a real safeguard rather than a marketing claim.

Easycoder is an AWS Advanced Partner working with healthcare providers, payers, and health technology companies across Australia and New Zealand on cloud, AI, and regulatory technology. If you are designing the human-in-the-loop for a clinical AI deployment, get in touch.